A name is a start. It is not the answer.

A peptide links protein building parts in a small chain. Insulin belongs to this group.

As of September 2026, US drug rules do not approve peptide care as a whole. Approval concerns a named medicine and what it is used to treat.

The useful next question is the product's exact name. A broad label such as wellness or peptide care does not tell you that name.

FDA-approved medicines include Ozempic and Wegovy, which contain semaglutide, and Mounjaro and Zepbound, which contain tirzepatide. Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy and Zepbound are approved for weight loss.

Approval is for a particular medicine and use. It does not cover everything called a peptide.

Ask which problem the medicine would address and whether you would take it as a pill or a shot.

Compounding is the making or mixing of a medicine for a patient's needs by a pharmacist or doctor.

The resulting medicine is not FDA-approved, even when the pharmacy holds a state licence.

Making a medicine to order may be allowed when no approved medicine can meet a patient's medical need. The person making it must still meet the compounding rules.

FDA warns that when weight-loss products carry research labels and are offered to people, their quality is unknown and they could cause harm.

A care visit does not remove this warning about a research-labelled product. Ask the clinician about that exact product, including its research label.